Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1996;28:615-621

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veelken, R.
Right arrow Articles by Schmieder, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veelken, R.
Right arrow Articles by Schmieder, R. E.

(Hypertension. 1996;28:615-621.)
© 1996 American Heart Association, Inc.


Articles

Epicardial Bradykinin B2 Receptors Elicit a Sympathoexcitatory Reflex in Rats

Roland Veelken; Alexander Glabasnia; Alexander Stetter; Karl F. Hilgers; Johannes F.E. Mann; Roland E. Schmieder

the Department of Internal Medicine, University of Erlangen-Nurnberg (Germany).

Correspondence to Roland Veelken, MD, Department of Medicine IV, University of Erlangen-Nurnberg, Loschgestraße 8½, 91054 Erlangen, FRG.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Bradykinin may be generated in the heart during ischemia and is involved in nociception. We tested the hypothesis that bradykinin elicits a sympathoexcitatory reflex in rats by stimulating cardiac afferent nerve fibers. Rats were implanted with femoral catheters for measurement of blood pressure and heart rate, a bipolar electrode for measurement of renal sympathetic nerve activity, and a pericardial catheter for intrapericardial injection of substances. Rats were slightly anesthetized with hexobarbital so pain reactions were prevented. Graded doses of bradykinin (2.5, 12, 25 µg) were injected intravenously or intrapericardially into control rats, intrapericardially after vagotomy, intrapericardially after intrapericardial pretreatment with the bradykinin B2 receptor antagonist Hoe 140, and intrapericardially after cardiac autonomic blockade (intrapericardial pretreatment with 10% procaine). For comparison, the serotonin 5-HT3 agonist phenylbiguanide, a substance known to elicit sympathoinhibitory reflexes by cardiac vagal afferents, and adenosine, putatively inducing sympathoexcitatory responses via the heart, were applied intrapericardially. Bradykinin increased blood pressure when administered intrapericardially but decreased blood pressure when injected intravenously; both intrapericardial and intravenous bradykinin increased renal sympathetic nerve activity. Intrapericardial adenosine had no effect on circulatory control. Intrapericardial pretreatment with the B2 receptor antagonist Hoe 140 completely inhibited the increases of blood pressure and renal sympathetic nerve activity in response to intrapericardial bradykinin but did not affect the responses to intrapericardial phenylbiguanide. Bilateral cervical vagotomy abolished the decreases of blood pressure, heart rate, and renal sympathetic nerve activity after intrapericardial phenylbiguanide but did not influence the responses to intrapericardial bradykinin. Cardiac autonomic blockade with intrapericardial procaine abolished all responses to bradykinin and phenylbiguanide. We conclude that cardiac bradykinin elicits a sympathoexcitatory reflex by epicardial B2 receptors in rats. The afferent portion of the reflex is most likely contained within sympathetic cardiac afferent fibers. Bradykinin may contribute to increased sympathetic nerve activity in pathophysiological situations of coronary artery disease and cardiac ischemia.


Key Words: receptors, bradykinin • bradykinin • adenosine • serotonin agonists • sympathetic nervous system


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Bradykinin is a potent vasodilator of blood vessels in the muscles, kidney, and viscera and also in the coronary circulation.1 2 Dilatation of systemic arteries causes a sharp fall in systolic and diastolic blood pressures (BPs).3 The substance can increase capillary permeability and produce edema.1 2 In this respect, it is involved in pain reactions2 and can evoke cardiovascular reflex responses of so far unknown physiological significance.4 5 6 In the heart, bradykinin is released in cardiac ischemia and myocardial infarction.7

Important afferent reflex pathways stimulated by bradykinin have their origin in the heart.4 6 8 9 10 11 12 13 The responses are generally believed to be mediated by cardiac sympathetic afferent fibers. However, there are conflicting reports on decreases and increases in BP, heart rate (HR), and sympathetic nerve activity as well as biphasic responses with respect to these parameters depending on the animal model used.9 10 11 14 Especially in the dog, the responses were difficult to predict.9 Vagotomy and sinoaortic denervation were used to avoid putatively confounding reflex responses after cardiac bradykinin application.11 However, vagotomy and sinoaortic denervation may have intrinsic and unpredictable effects on sympathetic outflow.

Bradykinin exerts its effects by stimulation of at least two bradykinin receptors, B1 and B2.15 16 B2 receptors are the naturally occurring receptors, and B1 receptors are scarce in normal tissue and expressed in situations of tissue damage.15 16 17 18 19 Selective B2 receptor antagonists such as Hoe 140 had to be available so that the role in rats of B2 receptors in a putatively sympathoexcitatory circulatory reflex arising from the heart could be addressed.20 21

We were interested in the putative ability of bradykinin to induce a sympathoexcitatory response characterized by increases in BP and renal sympathetic nerve activity (RSNA) via B2 receptors in intact rats. To test this hypothesis, we injected bradykinin into the pericardial sac before and after pretreatment with the selective B2 antagonist Hoe 140 to stimulate cardiac afferent fibers. Adenosine, which is said to induce a sympathoexcitatory response by similar reflex mechanisms,4 22 was used as a positive control. Phenylbiguanide, a serotonin 5-HT3 antagonist that induces hypotension, bradycardia, and sympathoinhibition by stimulating cardiac vagal afferent fibers, was used as a further control.23 24 We included cervically vagotomized rats and rats with cardiac autonomic blockade accomplished by instilling 10% procaine into the pericardial sac.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Male Sprague-Dawley rats (Ivanovas, Kisslegg, FRG) weighing 250 to 300 g were maintained in cages at 24±2°C. They were fed a standard rat diet (No. C-1000, Altromin) containing 0.2% sodium by weight and were allowed free access to tap water.

Preparations
All procedures done in rats were performed in accordance with the guidelines of the American Physiological Society and approved by the local government agency (Regierung von Mittelfranken, Ansbach, FRG). On the day of the experiment and under hexobarbital (30 mg/kg IV, Brevimytal, Eli Lilly) anesthesia, rats were equipped with one femoral arterial and two venous catheters. During the experiments, appropriate anesthesia was achieved with a maintenance infusion of hexobarbital (60 µg/100 g per minute IV) through one of the venous femoral catheters. We used this form of anesthesia to prevent pain reactions during intravenous or intrapericardial administration of bradykinin that might have influenced the response pattern.

Intrapericardial Catheter
As previously described,24 the intrapericardial catheter was constructed from a piece of thin silicone tubing (0.020-inch ID, 0.037-inch OD; Dow Corning) that was formed into an elliptical loop with the longest chord diameter of 2 cm. The loop was fixed with a suture, with the two open ends of the tubing leading out of the tubing being of equal length. One end was used for fluid administration into the pericardial space and the other for fluid withdrawal if more than 30 µL was administered intrapericardially.

Mechanical ventilation was instituted via a tracheal tube, and a high midline thoracotomy was performed. The lobes of the thymus were carefully separated, exposing a small portion of the pericardial sac adherent to the thymus. This part of the pericardial sac was opened, and the loop catheter was inserted into the pericardial sac and advanced toward the left side of the heart. The pericardial sac was closed by apposing the two lobes of the thymus and sealing them together with polyacrylic glue.24 25 Finally, the thorax was closed in layers and the open ends of the tubing extensions of the pericardial catheter were exteriorized at the nape. At the end of the respective experiments, 100 µL of concentrated methylene blue in isotonic saline was injected into the pericardial sac via the injection arm; leakage of dye from the pericardial space was assessed visually at autopsy. Only rats without leakage from the pericardial sac were used for final evaluation. The pericardial catheters had a dead space of 4 µL. This amount of saline was used to flush the catheter after injection of substances.

Renal sympathetic nerve recording was performed as described previously.23 24 26 Briefly, the left kidney was exposed through a flank incision, and a renal nerve bundle was dissected and placed on a bipolar stainless steel electrode (Cooner Wire Co). The amplified and filtered signal was channeled to an analog/digital oscilloscope (HM 512, Hameg) and a polygraph (model 7DA, Grass Instrument Co) for visual evaluation. An audio amplifier-loudspeaker (Grass model AM8) was used for auditory evaluation, and a rectifying voltage integrator (Grass model 7P10) was used. The integrated voltage signals were displayed on the polygraph. Fig 1Down shows an original tracing. The quality of the RSNA signal was assessed by its pulse synchronous rhythmicity and by examination of the magnitude of the decrease in recorded RSNA during ganglionic blockade with the short-acting ganglionic blocker trimethaphan (10 mg/kg IV) with an injection of methoxamine (10 µg IV). When an optimal signal was observed, the recording electrode was fixed to the nerve bundle with silicone adhesive (Sil-Gel 604, Wacker-Chemie). The electrode cable was then secured to the abdominal trunk muscles by a suture.



View larger version (16K):
[in this window]
[in a new window]
 
Figure 1. Representative recordings of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) in response to 25 µg bradykinin before and after cardiac bradykinin B2 receptor inhibition with Hoe 140.

For the experiments, the arterial catheter was connected to a transducer (Statham P23 Db) that was connected to a Grass polygraph for recording of BP and HR. A 1-hour equilibration and stabilization period was allowed.

Experimental Protocols
Protocol 1
Six anesthetized and instrumented Sprague-Dawley rats were injected in random order with 25 µg bradykinin either intravenously or intrapericardially. The rats were allowed a 20-minute recovery between each injection.

Protocol 2
Six anesthetized and instrumented Sprague-Dawley rats were injected in random order with 32 µg adenosine IV or 50, 200, and 500 µg adenosine IPC. The rats were allowed a 20-minute recovery between each injection.

Protocol 3
Six anesthetized and instrumented Sprague-Dawley rats were injected with 2.5, 12, and 25 µg bradykinin IPC and 0.9, 9, and 90 µg phenylbiguanide IPC in random order before and after intrapericardial pretreatment with 200 µg of the B2 receptor antagonist Hoe 140. The rats were allowed a 20-minute recovery between each injection. In this and the subsequent protocols, the B2 receptor antagonist was administered in a volume of 40 µL and the bradykinin and phenylbiguanide boluses in portions of 30 µL each.

Protocol 4
Six anesthetized and instrumented Sprague-Dawley rats were injected with 2.5, 12, and 25 µg bradykinin IPC and 0.9, 9, and 90 µg phenylbiguanide IPC in random order before and after bilateral cervical vagotomy performed by cutting the vagus nerves close to the bifurcation of the common carotid arteries. The rats were allowed a 20-minute recovery between each injection. Rats had to be intubated as their respiration was impaired after bilateral cervical vagotomy because the recurrent nerves were also cut.

Protocol 5
Six anesthetized and instrumented Sprague-Dawley rats were injected with 2.5, 12, and 25 µg bradykinin IPC and 0.9, 9, and 90 µg phenylbiguanide IPC in random order before and after intrapericardial pretreatment with 30 µL of 10% procaine. After dose-response curves were obtained without cardiac autonomic blockade first, a 50-µL bolus of 10 µg methoxamine was injected via the second line in the femoral vein to prove proper neurally mediated bradycardia by stimulation of the arterial baroreceptor reflex. BP, HR, and RSNA changes were assessed. A 10% procaine solution (30 µL) was injected into the pericardial sac, and 5 minutes later, methoxamine was given again. After 5 minutes, the methoxamine injection no longer induced reflex bradycardia in rats with properly implanted intrapericardial catheters. This was interpreted as a sign of proper blockade of efferent and afferent cardiac fibers.27 28 29 30 Three minutes later, either bradykinin or phenylbiguanide was injected as soon as all parameters had returned to baseline values. Thereafter, a further bolus injection of methoxamine was administered to prove ongoing proper cardiac autonomic blockade. Before each dose of bradykinin and phenylbiguanide, additional injections of 30 µL of 10% procaine into the pericardial sac were necessary because the cardiac autonomic blockade lasted only for 15 minutes. Fluid was removed from the pericardial sac and the methoxamine test repeated again as described above. Since the responses to injections of the highest doses of bradykinin and phenylbiguanide never lasted more than 3.5 minutes, the cardiac autonomic blockade achieved with procaine was sufficient.

Protocol 6
Four anesthetized and instrumented Sprague-Dawley rats were injected with six consecutive doses of 25 µg bradykinin IPC. The drug was given every 20 minutes.

Drugs
Adenosine, bradykinin, methoxamine, phenylbiguanide, and procaine were purchased from Sigma Chemical Co. Trimethaphan camsylate (Arfonad, Hoffmann–La Roche) was provided by Roche Laboratories. The B2 antagonist Hoe 140 was donated courtesy of Dr Schoelkens of Hoechst, Frankfurt, Germany. All drugs except for the previously dissolved trimethaphan were dissolved in saline and prepared anew for every experiment.

Data Analyses
Integrated RSNA was expressed as microvolts integrated over 1-second intervals. The background noise level was recorded as postmortem activity (average of 30 minutes) and subtracted from the measured nerve activity. Because of the limitations of comparing values from multifiber sympathetic nerves between rats, the data are expressed as percent change from control values.

The measured parameters were compared at baseline, maximal response, and recovery before and after drug administration. Furthermore, we tested for possible changes of baseline parameters after administering procaine intrapericardially, cervical vagotomy, or intravenous injection of the B2 receptor antagonist. The data were statistically analyzed by ANOVA and Newman-Keuls post hoc test31 with the CSS statistical software package (StatSoft Inc). Only a priori fixed comparisons were tested. Statistical significance was defined as a value of P<.05. All data are given as mean±SE.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Protocol 1
Protocol 1 evaluated the possibility of distinguishing between intrapericardial and intravenous application of bradykinin by the evoked response pattern in intact rats (Fig 2Down). Before intrapericardial or intravenous drug administration, baseline BP and HR were 90±6 mm Hg and 400±21 beats per minute (bpm), respectively. ANOVA showed that basal control levels between the injections were not different from these preexperimental values. The two injections were given in random order. Intrapericardial injection of 25 µg bradykinin unequivocally induced marked increases of BP, whereas intravenous application decreased it. The increases in RSNA were nominally not significantly different from each other. HR was not significantly altered after both modes of application. After intrapericardial bradykinin, BP returned to baseline values after 177±9 seconds and RSNA after 184±10 seconds. The time points for intravenous injections of bradykinin were as follows: BP, 175±9 seconds and RSNA, 179±14 seconds.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 2. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial or intravenous injection of 25 µg bradykinin.

Protocol 2
Protocol 2 evaluated the effects of intravenous administration of adenosine (32 µg) versus graded intrapericardial application of adenosine (50, 250, 500 µg) on BP, HR, and RSNA responses (Fig 3Down). Before administration of any drug, baseline BP and HR were 97±6 mm Hg and 388±19 bpm, respectively. ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. Whereas administration of 32 µg adenosine IV led to decreases in BP and HR as well as increases in RSNA, even 500 µg adenosine IPC was not followed by any significant change in the recorded parameters.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 3. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (i.p.c.) injection of 32 µg adenosine or intravenous (i.v.) injections of 50, 250, and 500 µg adenosine.

Protocol 3
Protocol 3 evaluated the effects of intrapericardial administration of the specific B2 receptor antagonist Hoe 140 on BP, HR, and RSNA responses to graded doses of bradykinin and phenylbiguanide (Figs 1 and 4UpDown). Before administration of any drug, baseline BP and HR were 94±6 mm Hg and 380±21 bpm, respectively. ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. Before the administration of the B2 receptor antagonist, bradykinin and phenylbiguanide affected BP, HR, and RSNA dose dependently. Bradykinin increased BP and RSNA, and phenylbiguanide decreased BP, HR, and RSNA. Intrapericardial administration of the B2 receptor antagonist did not affect baseline parameters. After pretreatment with the B2 receptor antagonist, the responses of BP, HR, and RSNA to intrapericardial bradykinin were abolished and those to phenylbiguanide injection were preserved. After the highest dose of bradykinin, BP returned to baseline values after 177±6 seconds and RSNA after 179±13 seconds during the control period. The respective time points for the highest dose of phenylbiguanide were as follows: BP, 176±9 seconds; HR, 162±9 seconds; and RSNA, 185±12 seconds.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 4. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (ipc) injections of 2.5, 12, and 25 µg bradykinin and 0.9, 9, and 90 µg phenylbiguanide (PBG) before and after intrapericardial administration of the bradykinin B2 receptor antagonist Hoe 140.

Protocol 4
Protocol 4 evaluated the effects of bilateral vagotomy on BP, HR, and RSNA responses to graded doses of bradykinin and phenylbiguanide (Fig 5Down). Baseline BP and HR assessed before administration of any drug were 97±8 mm Hg and 405±18 bpm, respectively. Again, ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. Before cervical vagotomy was induced, administration of bradykinin and phenylbiguanide affected BP, HR, and RSNA dose dependently as described above. After bilateral cervical vagotomy, the responses to phenylbiguanide were abolished, whereas the responses to bradykinin were unaffected. After the highest dose of bradykinin, BP returned to baseline values after 178±6 seconds and RSNA after 183±9 seconds. The respective time points for the highest dose of phenylbiguanide during the control period were as follows: BP, 173±9 seconds; HR, 162±7 seconds; and RSNA, 183±7 seconds.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 5. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (ipc) injections of 2.5, 12, and 25 µg bradykinin and 0.9, 9, and 90 µg phenylbiguanide (PBG) before and after bilateral cervical vagotomy.

Protocol 5
Protocol 5 evaluated the effects of graded doses of bradykinin and phenylbiguanide on BP, HR, and RSNA responses after cardiac autonomic blockade with 10% procaine (Fig 6Down). Before administration of any drug, baseline BP and HR were 94±6 mm Hg and 380±21 bpm, respectively. ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. During the control period, bradykinin and phenylbiguanide affected BP, HR, and RSNA dose dependently. After the highest dose of bradykinin, BP returned to baseline values after 173±8 seconds and RSNA after 187±10 seconds. The respective time points for the highest dose of phenylbiguanide were as follows: BP, 170±7 seconds; HR, 165±6 seconds; and RSNA, 180±12 seconds. Bradykinin increased BP and RSNA, whereas phenylbiguanide decreased BP, HR, and RSNA. Intrapericardial administration of procaine only transiently affected baseline parameters. Pretreatment with procaine abolished the responses of BP, HR, and RSNA to intrapericardial bradykinin and phenylbiguanide. After the first injection of 10% procaine into the pericardial sac, mean arterial BP was lowered from 94±6 to 88±4 mm Hg for about 5 minutes. HR exhibited only a transient decrease of -32±9 bpm for about 1 minute. RSNA did not change significantly. After cardiac autonomic blockade with intrapericardial procaine, the responses of the measured parameters to both phenylbiguanide and bradykinin were completely inhibited.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 6. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (ipc) injections of 2.5, 12, and 25 µg bradykinin and 0.9, 9, and 90 µg phenylbiguanide (PBG) before and after cardiac autonomic blockade with intrapericardial administration of 10% procaine.

Protocol 6
Protocol 6 evaluated the effects of six consecutive doses of 25 µg bradykinin IPC on BP and RSNA responses (TableDown). Injections were given every 20 minutes. There were no significant changes in the responses of the measured parameters, nor were there significant alterations in the time course of these responses (time of maximal response, time of recovery).


View this table:
[in this window]
[in a new window]
 
Table 1. Blood Pressure and Renal Sympathetic Nerve Activity Responses to Six Consecutive Intrapericardial Injections of Bradykinin (25 µg)


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Our results demonstrate that cardiac B2 receptors are able to induce a marked sympathoexcitatory response most likely via cardiac sympathetic afferent fibers. Bradykinin given intrapericardially elicited a quite different response of mean arterial BP than when injected intravenously at the same dose: In the first case, BP increased, and in the latter, BP decreased. Intravenous bradykinin is a potent vasodilator.1 Hence, the increases of RSNA after intravenous bradykinin were most likely mediated by the baroreceptor reflex caused by the induced hypotension.32 33 However, the increases of RSNA and BP in response to intrapericardial bradykinin should have been mediated by neurogenic mechanisms depending on cardiac afferent nerve traffic.10

It is known that bradykinin stimulates sympathetic afferent fibers from the heart.4 8 34 35 However, systemic cardiovascular responses have not been uniform and often have been depressant: Excitatory responses have been observed in cats.14 36 In rabbits11 and monkeys,9 cardiac bradykinin produced reflex decreases of BP, HR, and sympathetic nerve activity. In dogs, activation of cardiac sympathetic afferents with bradykinin resulted in inhibitory and excitatory as well as biphasic responses.13 37

The bradykinin receptor mediating the majority of the bradykinin effects is the B2 receptor.16 In rats, these receptors have been found in the dorsal root ganglia, the spinal cord, and the area close to the cerebral ventricle.38 39 40 These findings suggest that B2 receptors are an important part of visceral autonomous pathways and reflexes.

B1 receptors are synthesized under inflammatory and ischemic conditions.16 17 The fact that bradykinin is released especially during myocardial ischemia7 18 might suggest a role of B1 receptors under these pathophysiological conditions. The existence of a subgroup of cardiac afferent sympathetic fibers synthesizing B1 receptors under special conditions is not completely unlikely.41 42 43 44 However, our results in rats demonstrate that cardiac afferent fibers with B2 receptors alone are capable of eliciting a uniform sympathoexcitatory reflex that could instantly influence the neural control of the circulation without the aid of an additional receptor class being partly dependent on de novo synthesis.

The bradykinin inhibitor Hoe 140 proved to be quite specific and did not influence the responses to intrapericardial phenylbiguanide.20 Phenylbiguanide has been shown to be a serotonin 5-HT3 receptor agonist that specifically stimulates cardiac vagal afferents if the drug is injected intrapericardially or intravenously.23 24 Both injection routes induced the classic features of the Bezold-Jarisch reflex (hypotension, bradycardia, and sympathoinhibition). On the other hand, intrapericardial bradykinin was characterized by increases of BP and RSNA.

It is assumed that chemostimulation of vagal cardiac afferents induces depressor responses by influencing neural control of the circulation, whereas chemostimulation of cardiac sympathetic afferents may mediate sympathoexcitation and be involved in nociception.8 Bradykinin could theoretically stimulate vagal afferents that are involved in cardiovascular control and nociception. However, in our experiments, vagotomy did not alter the responses to intrapericardial bradykinin. This suggests that the afferent information was most likely transmitted to the central nervous system by sympathetic afferent fibers.

We induced cardiac autonomic blockade by repetitive injections of 10% procaine into the pericardial sac. Several authors have used this method in different animal models.27 28 29 30 45 46 Our experiments with intrapericardial procaine demonstrate that the responses to bradykinin and phenylbiguanide injected into the pericardial sac were indeed of cardiac origin.

We used adenosine as a control substance because it occurs endogenously under conditions comparable to those of bradykinin and is also said to stimulate cardiac sympathetic afferent fibers.4 We were not able to elicit any responses by intrapericardial application of adenosine. Since we measured only efferent and not afferent sympathetic nerve activity, it is possible that afferent sympathetic nerve traffic was increased, playing a role in, for instance, nociception but not being involved in the neural control of circulation.8 Since reflex responses to adenosine were observed during acute cardiac ischemia in dogs, these responses of adenosine might depend on facilitating circumstances such as local increases in H+ proton concentration, oxygen free radicals, and/or generation of various mediator substances and related receptors.8 16 43 44 47 48 The assumption that adenosine could depend on unknown confounding conditions is further supported by the fact that direct recordings of cardiac sympathetic C fibers showed conflicting results in the same animal model: Whereas Montano et al22 observed marked increases of cardiac sympathetic C-fiber activity after intracoronary injection of adenosine in the cat, Pan and Longhurst36 could detect no response of cardiac sympathetic C fibers after either intracoronary or intrapericardial administration of this drug in cats with coronary ischemia.

Our results demonstrate that local bradykinin can evoke a powerful excitatory reflex. Notably, the sympathoexcitation occurred when all other cardiovascular reflex mechanisms (arterial baroreceptor reflex, cardiopulmonary reflexes with vagal afferents) were left intact and could have compensated. Hence, cardiac B2 receptors might play an important role in circulatory control, when bradykinin is released locally, eg, during cardiac ischemia.


*    Acknowledgments
 
This work was supported by a grant-in-aid (Ve104\2-2) from the Deutsche Forschungsgemeinschaft, Bonn-Bad Godesberg, Germany.


*    Footnotes
 
Presented in part at the annual meeting of the American Heart Association, Dallas, Tex, November 14-17, 1994.

Received December 14, 1995; first decision February 6, 1996; accepted June 18, 1996.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-47.[Medline] [Order article via Infotrieve]

2. Marceau F, Lussier A, Regoli D, Giroud JP. Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol. 1983;14:209-229.[Medline] [Order article via Infotrieve]

3. Margolius HS. Tissue kallikreins and kinins: regulation and role in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol. 1989;29:343-364.[Medline] [Order article via Infotrieve]

4. Thames MD, Kinugawa T, Dibner-Dunlap ME. Reflex sympathoexcitation by cardiac sympathetic afferents during myocardial ischemia: role of adenosine. Circulation. 1993;87:1698-1704.[Abstract/Free Full Text]

5. Bauer MB, Meller ST, Gebhart GF. Bradykinin modulation of a spinal nociceptive reflex in the rat. Brain Res. 1992;578:186-196.[Medline] [Order article via Infotrieve]

6. Evans RG, Ludbrook J, Michalicek J. Use of nicotine, bradykinin and veratridine to elicit cardiovascular chemoreflexes in unanaesthetized rabbits. Clin Exp Pharmacol Physiol. 1991;18:245-254.[Medline] [Order article via Infotrieve]

7. Kimura E, Hashimoto K, Furukawa S, Hayakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J. 1973;85:635-647.[Medline] [Order article via Infotrieve]

8. Meller ST, Gebhart GF. A critical review of the afferent pathways and the potential chemical mediators involved in cardiac pain. Neuroscience. 1992;48:501-524.[Medline] [Order article via Infotrieve]

9. Gorman AJ, Zucker IH, Gilmore JP. Renal nerve responses to cardiac receptor stimulation with bradykinin in monkeys. Am J Physiol. 1983;244:F659-F665.

10. Gorman AJ, Zucker IH. Renal nerve and blood pressure responses to stimulation of cardiac receptors in dogs and cats by bradykinin. Basic Res Cardiol. 1984;79:142-154.[Medline] [Order article via Infotrieve]

11. Niitani S, Tomomatsu E, Ohba H, Yoshida Y, Yagi S. Renal nerve and cardiovascular responses to cardiac receptor stimulation in rabbits. Am J Physiol. 1988;254:R192-R196.[Abstract/Free Full Text]

12. Armour JA, Yuan BX, Butler CK. Cardiac responses elicited by peptides administered to canine intrinsic cardiac neurons. Peptides. 1990;11:753-761.[Medline] [Order article via Infotrieve]

13. Minisi AJ, Thames MD. Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circulation. 1993;87:240-246.[Abstract/Free Full Text]

14. Reimann KA, Weaver LC. Contrasting reflexes evoked by chemical activation of cardiac afferent nerves. Am J Physiol. 1980;239:H316-H325.

15. Sharma JN. Therapeutic prospects of bradykinin receptor antagonists. Gen Pharmacol. 1993;24:267-274.[Medline] [Order article via Infotrieve]

16. Regoli D, Jukic D, Gobeil F, Rhaleb NE. Receptors for bradykinin and related kinins: a critical analysis. Can J Physiol Pharmacol. 1993;71:556-567.[Medline] [Order article via Infotrieve]

17. Campos AH, Calixto JB. Mechanisms involved in the contractile responses of kinins in rat portal vein rings: mediation by B1 and B2 receptors. J Pharmacol Exp Ther. 1994;268:902-909.[Abstract/Free Full Text]

18. Chahine R, Adam A, Yamaguchi N, Gaspo R, Regoli D, Nadeau R. Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol. 1993;108:318-322.[Medline] [Order article via Infotrieve]

19. Webb M, McIntyre P, Phillips E. B1 and B2 bradykinin receptors encoded by distinct mRNAs. J Neurochem. 1994;62:1247-1253.[Medline] [Order article via Infotrieve]

20. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:771-772.[Medline] [Order article via Infotrieve]

21. Steranka LR, Farmer SG, Burch RM. Antagonists of B2 bradykinin receptors. FASEB J. 1989;3:2019-2025.[Abstract]

22. Montano N, Lombardi F, Ruscone TG, Contini M, Guazzi M, Malliani A. Effetto eccitatorio dell'adenosina sull'attivita di scarica delle fibre afferenti simpatiche cardiache. Cardiologia. 1991;36:953-959.[Medline] [Order article via Infotrieve]

23. Veelken R, Hilgers KF, Leonard M, Ruhe J, Scrogin K, Mann JFE, Luft FC. A highly selective cardiorenal, serotonergic 5-HT3-mediated reflex in rats. Am J Physiol. 1993;264:H1871-H1877.[Abstract/Free Full Text]

24. Veelken R, Sawin LL, DiBona GF. Epicardial 5-HT3 receptors in circulatory control in conscious Sprague Dawley rats. Am J Physiol. 1990;258:H466-H472.[Abstract/Free Full Text]

25. Veelken R, Schelling P, Unger T. An approach to measuring cardiac output with Doppler flow probes in conscious rats. Am J Physiol. 1988;255:H1206-H1210.[Abstract/Free Full Text]

26. Veelken R, Sawin LL, DiBona GF. Dissociation of renal nerve and excretory responses to volume expansion in prehypertensive Dahl salt-sensitive and salt-resistant rats. Hypertension. 1989;13:822-827.[Abstract/Free Full Text]

27. Dorward PK, Bell LB, Rudd CD. Cardiac afferents attenuate renal sympathetic baroreceptor reflexes during acute hypertension. Hypertension. 1990;16:131-139.[Abstract/Free Full Text]

28. Dorward PK, Riedel W, Burke SL, Oliver JR, Korner PI. The renal sympathetic baroreflex in the rabbit: arterial and cardiac baroreceptor influences, resetting and the effect of anesthesia. Circ Res. 1985;57:618-633.[Abstract/Free Full Text]

29. Arndt JO, Pasch U, Samodelov LF, Wiebe H. Reversible blockade of myelinated and non-myelinated cardiac fibers in cats by instillation of procaine into the pericardium. Cardiovasc Res. 1981;15:61-67.[Medline] [Order article via Infotrieve]

30. Samodelov LF, Pohl M, Arndt JO. Reversible blockade of cardiac efferents with procaine instilled into the pericardium. Cardiovasc Res. 1982;16:187-193.[Medline] [Order article via Infotrieve]

31. Wallenstein S, Zucker IH, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.[Abstract/Free Full Text]

32. Numao Y, Siato M, Terui N, Kumada M. The aortic nerve-sympathetic reflex in the rat. J Auton Nerv Syst. 1985;13:65-79.[Medline] [Order article via Infotrieve]

33. Judy WV, Farrell SK. Arterial baroreceptor reflex control of sympathetic nerve activity in the spontaneously hypertensive rat. Hypertension. 1979;1:605-614.[Abstract/Free Full Text]

34. Pan HL, Stebbins CL, Longhurst JC. Bradykinin contributes to the exercise pressor reflex: mechanism of action. J Appl Physiol. 1993;75:2061-2068.[Abstract/Free Full Text]

35. Woolley G, Staszewska Woolley J. A role for cyclic GMP in the initiation of cardiac pressor reflexes by bradykinin and capsaicin. Pol J Pharmacol Pharm. 1990;42:249-257.[Medline] [Order article via Infotrieve]

36. Pan H, Longhurst JC. Lack of a role of adenosine in activation of ischemically sensitive cardiac sympathetic afferents. Am J Physiol. 1995;269:H106-H113.[Abstract/Free Full Text]

37. Felder RB, Thames MD. Responses to activation of cardiac sympathetic afferents with epicardial bradykinin. Am J Physiol. 1982;242:H148-H153.

38. Bauer MB, Simmons ML, Murphy S, Gebhart GF. Bradykinin and capsaicin stimulate cyclic GMP production in cultured rat dorsal root ganglion neurons via a nitrosyl intermediate. J Neurosci Res. 1993;36:280-289.[Medline] [Order article via Infotrieve]

39. Lopes P, Regoli D, Couture R. Cardiovascular effects of intrathecally administered bradykinin in the rat: characterization of receptors with antagonists. Br J Pharmacol. 1993;110:1369-1374.[Medline] [Order article via Infotrieve]

40. Gerken VM, Santos RA. Centrally infused bradykinin increases baroreceptor reflex sensitivity. Hypertension. 1992;19(suppl II):II-176-II-181.

41. Baker DG, Coleridge HM, Coleridge JCG. Vagal afferent C fibers from the ventricle. In: Hainsworth R, Kidd C, Linden RJ, eds. Cardiac Receptors. Cambridge, UK: Cambridge University Press; 1979:117-137.

42. Bishop V, Malliani A, Thoren P. Cardiac mechanoreceptors. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System, Volume III, Peripheral Circulation and Organ Blood Flow. Bethesda, Md: American Physiological Society; 1983:497-555.

43. Ustinova EE, Schultz HD. Activation of cardiac vagal afferents in ischemia and reperfusion: prostaglandins versus oxygen-derived free radicals. Circ Res. 1994;74:904-911.[Abstract/Free Full Text]

44. Ustinova EE, Schultz HD. Activation of cardiac vagal afferents by oxygen-derived free radicals in rats. Circ Res. 1994;74:895-903.[Abstract/Free Full Text]

45. Ludbrook J, Graham WF. The role of cardiac receptor and arterial baroreceptor reflexes in control of circulation during acute changes of blood volume in the conscious rabbit. Circ Res. 1985;54:424-435.[Abstract/Free Full Text]

46. Evans RG, Hayes IP, Ludbrook J, Ventura S. Factors confounding blockade of cardiac afferents by intrapericardial procaine in conscious rabbits. Am J Physiol. 1993;264(part 2):H1861-H1870.

47. Zanzinger J, Bassenge E. Coronary vasodilation to acetylcholine, adenosine and bradykinin in dogs: effects of inhibition of NO-synthesis and captopril. Eur Heart J. 1993;14(suppl 1):164-168.

48. Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc Res. 1994;28:209-214.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L.-W. Fu, A. Phan, and J. C. Longhurst
Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2?
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2530 - H2540.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. LeFebvre, A. Shintani, T. Gebretsadik, J. R. Petro, L. J. Murphey, and N. J. Brown
Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor Blockade
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1261 - 1267.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Qin, J. P. Farber, K. E. Miller, and R. D. Foreman
Responses of thoracic spinal neurons to activation and desensitization of cardiac TRPV1-containing afferents in rats
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1700 - R1707.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
M. R Zahner, D.-P. Li, S.-R. Chen, and H.-L. Pan
Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats
J. Physiol., September 1, 2003; 551(2): 515 - 523.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G.-Q. Zhu, K. P. Patel, I. H. Zucker, and W. Wang
Microinjection of ANG II into paraventricular nucleus enhances cardiac sympathetic afferent reflex in rats
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2039 - H2045.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D.-P. Li, D. B. Averill, and H.-L. Pan
Differential roles for glutamate receptor subtypes within commissural NTS in cardiac-sympathetic reflex
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R935 - R943.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Saino, G. Pomidossi, R. Perondi, A. Morganti, L. Turolo, and G. Mancia
Modulation of Sympathetic Coronary Vasoconstriction by Cardiac Renin-Angiotensin System in Human Coronary Heart Disease
Circulation, May 16, 2000; 101(19): 2277 - 2283.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Cinca and A. Rodriguez-Sinovas
Cardiovascular reflex responses induced by epicardial chemoreceptor stimulation
Cardiovasc Res, January 1, 2000; 45(1): 163 - 171.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
H.-L. Pan, J. C Longhurst, J. C Eisenach, and S.-R. Chen
Role of protons in activation of cardiac sympathetic C-fibre afferents during ischaemia in cats
J. Physiol., August 1, 1999; 518(3): 857 - 866.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Hatta, R. Maruyama, S. J. Marshall, M. Imamura, and R. Levi
Bradykinin Promotes Ischemic Norepinephrine Release in Guinea Pig and Human Hearts
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 919 - 927.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L.-W. Fu and J. C. Longhurst
Reflex pressor response to arterial phenylbiguanide: role of abdominal sympathetic visceral afferents
Am J Physiol Heart Circ Physiol, December 1, 1998; 275(6): H2025 - H2035.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veelken, R.
Right arrow Articles by Schmieder, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veelken, R.
Right arrow Articles by Schmieder, R. E.